Ok how about this as a starting point?
Amplia Therapeutics Annual Report YE 31/3/23 pg48 “going concern” and audit report pg65
Pharmaxis AR YE 30/6/23 pg33 “going concern” and audit report pg62
Mesoblast AR YE 30/6/24 pg6 “Risks; accumulated deficit $908.8 million; require substantial additional financing” and pg169 “going concern - material uncertainty”
Neuren Pharmaceuticals AR YE 31/12/20 pg36 “material uncertainties and going concern basis”
Actinogen Medical AR YE 30/6/23 pg43 “going concern” and audit report pg64
I think you now owe me an apology and you need to consider retracting your comments in relation to my post!
Screenshot(s) from Annual Report of 29 Aug 24, page-10
Add CYP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
27.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $50.13M | |||
| Open | High | Low | Value | Volume |
| 27.5¢ | 27.8¢ | 27.0¢ | $9.193K | 33.99K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 32056 | 26.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 27.5¢ | 2271 | 1 |
View Market Depth
| Last trade - 10.48am 08/10/2024 (20 minute delay) ? |
| CYP (ASX) Chart |